Replies to post #2567 on UniCycive Therapeutics Inc (UNCY)

[Stumblebum]

I agree with your comments 100%….yes definitely overblown selling….thats why I’ve been adding the last two days….need to stop soon or might have to submit a 13g myself

[Whalatane]

Re

As of November 14, 2025, Amendment No. 1 to the Sales Agreement increases the maximum aggregate offering price that may be sold in the ATM offering to $100,000,000.
The ATM offering allows the company to issue and sell shares from time to time".

Great DD ...thx

So in full disclosure ...I'm fine with the market losing interest and the PPS trailing down over the next 3 mths . I prefer to buy when most regret ever buying the stock , or have lost interest ...if I believe in the fundamental story for the Co....Recent history of RZLT as example.

I doubt we see an early approval. This is not an unmet need . There are other pho binders readily available in the clinic already in use by these patients . They just dont like what they have for all the reasons we've discussed.

IMHO this ultimately ends up with a bidding war between Novartis ( credit to Stumble for making me take a harder look at Novartis ) ...and CSL-Vifor who were my first choice.
This will especially play out for the EU market .
Novartis is a huge kidney care provider in the EU with well established govt and health dept connections .
CSL-Vifor îs already firmly entrenched in EU dialysis centers with their kidney care meds ....AND is in partnership with Fresenius .
Fresenius is the #1 dialysis provider in the EU and has about 40% of the US market

Both Co's can ramp up use of OLC in the EU 10x faster than if UNCY tried to do it themselves
How this deal works out ...outright sale or partnership in the EU remains to be seen but IMHO one or the other is inevitable.

Novartis has huge cash resources and would probably want full control ....but will definitely wait till FDA approved and the TDAPA process initiated .
CSL Vifor may be more willing to partner with less $ invested and may start talks pre approval .

JMO
Kiwi

[Whalatane]

Re

I think the sell off is an over reaction, JMO.

Good call . If you or anyone else reading this has some free time ...can you offer an opinion on extending the patents .
Hatch Waxman ...for you long time AMRN holders ...has a provision in the US
The EU may be easier .

Extending the patents ..if it happens ..would be huge for UNCY as it would definitely cement Novartis as a major suitor ...especially for the EU .
You Amarinites reading this ...you know how long it took AMRN to get Vaskepa on the market in the various EU countries . Same would happen if UNCY tried to do it themselves .
Novartis is entrenched in the EU health depts
JMO
Kiwi